← FDA DRUG APPROVALS

FDA ANDA · ANDA065040

CYCLOSPORINE

Sponsor: APOTEX

APPLICATION
ANDA065040
TYPE
ANDA
ORIGINAL APPROVAL
2002-05-09
LATEST ACTION
2025-08-01
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription

Products

CYCLOSPORINEPrescription
CYCLOSPORINE 25MG · CAPSULE · ORAL
CYCLOSPORINEPrescription
CYCLOSPORINE 100MG · CAPSULE · ORAL

Approval history

2025-08-01Labeling · Supplement 16 · standardAP
2025-08-01Labeling · Supplement 20 · standardAP
2014-02-26Labeling · Supplement 8AP
2014-02-26Labeling · Supplement 9 · standardAP
2006-06-27Labeling · Supplement 5AP
2006-05-08Labeling · Supplement 4AP
2002-05-09OriginalReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →